WO2021195521A1 - Méthodes de traitement d'infections à coronavirus - Google Patents

Méthodes de traitement d'infections à coronavirus Download PDF

Info

Publication number
WO2021195521A1
WO2021195521A1 PCT/US2021/024399 US2021024399W WO2021195521A1 WO 2021195521 A1 WO2021195521 A1 WO 2021195521A1 US 2021024399 W US2021024399 W US 2021024399W WO 2021195521 A1 WO2021195521 A1 WO 2021195521A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
emetine
subject
effective amount
Prior art date
Application number
PCT/US2021/024399
Other languages
English (en)
Inventor
Christopher Schelling
Juan Jose Marugan
Noel T. Southall
Mark J. Henderson
Marc Ferrer
Original Assignee
Acer Therapeutics Inc.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc., The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical Acer Therapeutics Inc.
Publication of WO2021195521A1 publication Critical patent/WO2021195521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • Coronaviruses act as cross-species viruses with the potential to rapidly spread into new host species and cause epidemic diseases, as demonstrated by the Middle East respiratory syndrome CoV (MERS-CoV), severe acute respiratory syndrome CoV (SARS-CoV), and the cause of the COVID-19 pandemic, SARS-CoV-2.
  • CoVs represent a group of enveloped, positive-sense, single-stranded viruses with large genomes (27 to 33 kb) and are capable of causing respiratory, enteric, hepatic, and neurological diseases of differing severities.
  • CoV infections are difficult to prevent and cure.
  • CoV replication machinery exhibits substantial proofreading activity, estimates of the nucleotide mutation rate in CoVs are moderate to high relative to that of other single-stranded RNA viruses.
  • the large RNA genome in CoVs allows for extra plasticity in genome modification by recombination.
  • drugs such as ribavirin, lopinavir-ritonavir, interferon, and corticosteroids have been used to treat patients infected with SARS-CoV or MERS-CoV.
  • contradictory findings on their efficacy and concerns over tolerability and clinical benefit have limited the use of antiviral therapeutics for CoVs.
  • a need exists for therapeutic agents for treating diseases causes by coronaviruses, particularly SARS-CoV-2.
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and wherein the subject does not require hospitalization.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • a composition comprising a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), and wherein the subject does not require hospitalization.
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • methods of treating COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • “about” means ⁇ 5% of a given value or range. In some embodiments, “about” means ⁇ 4% of a given value or range. In some embodiments, “about” means ⁇ 3% of a given value or range. In some embodiments, “about” means ⁇ 2% of a given value or range. In some embodiments, “about” means ⁇ 1% of a given value or range. In another embodiment, about means ⁇ 0.5% of a given value or range. In some embodiments, “about” means ⁇ 0.05% of a given value or range.
  • “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for human or veterinary pharmaceutical use.
  • the term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable.
  • “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene- sulfonic acid, salicylic acid, and the like.
  • pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines.
  • suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2- dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
  • administering refers to introducing an agent into a patient.
  • a therapeutic amount can be administered to the patient, which can be determined by the treating physician, medical professional, or the like.
  • an oral route of administration is preferred.
  • the related terms and phrases “administering” and “administration of,” when used in connection with a compound or tablet (and grammatical equivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by self administration by the patient, and/or to indirect administration, which may be the act of prescribing a drug. Administration entails delivery to the patient of the drug.
  • dose refers to the total amount of an active agent (e.g., emetine or a pharmaceutically acceptable salt thereof) administered to a patient in a single day (24-hour period).
  • the desired dose can be administered once daily.
  • the desired dose may be administered in one, two, three, four or more sub-doses at appropriate intervals throughout the day, where the cumulative amount of the sub-doses equals the amount of the desired dose administered in a single day.
  • dose and “dosage” are used interchangeably herein.
  • therapeutically effective amount refers to an amount of a drug or an agent (e.g., emetine or a pharmaceutically acceptable salt thereof) that when administered to a patient suffering from a condition, will have the intended therapeutic effect, e.g., alleviation, amelioration, palliation or elimination of one or more manifestations of the condition in the patient.
  • the full therapeutic effect does not necessarily occur by administration of one dose, and can occur only after administration of a series of doses and can be administered in one dose form or multiples thereof.
  • 500 mg of the drug can be administered in a single 500 mg strength tablet or two 250 mg strength tablets.
  • a therapeutically effective amount may be administered in one or more administrations.
  • the term “patient” refers to a mammal, such as a human, bovine, rat, mouse, dog, monkey, ape, goat, sheep, cow, or deer.
  • a patient as described herein can be a human.
  • treatment covers the treatment of a human patient, and includes: (a) reducing the risk of occurrence of the condition in a patient determined to be predisposed to the disease but not yet diagnosed as having the condition, (b) impeding the development of the condition, and/or (c) relieving the condition, i.e., causing regression of the condition and/or relieving one or more symptoms of the condition.
  • COVID-19 refers to the coronavirus disease caused by the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was also previously known as the 2019 novel coronavirus.
  • Emetine is used mainly as an antiprotozoal and an emetic.
  • the chemical name of emetine is (2S,3R,l lbS)-2-(((R)-6,7-dimethoxy-l,2,3,4-tetrahydroisoquinolin-l-yl)methyl)-3-ethyl- 9,10-dimethoxy-l,3,4,6,7,l lb-hexahydro-2H-pyrido[2,l-a]isoquinoline, and the compound has the following structure:
  • Emetine or pharmaceutically acceptable salts thereof (such as emetine dihydrochloride hydrate), also are commercially available.
  • emetine is administered as a hydrochloride salt thereof.
  • Cephaeline also known as (lf?)-l-[[(2ri',3f?,l lbri)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,l lb- hexahydro- l//-pyrido[2, 1 -c/]isoquinolin-2-yl]methyl]-7-methoxy- l ,2,3,4-tetrahydroisoquinolin-6-ol, has the following chemical structure:
  • Cephaeline is commercially available.
  • Dehydroemetine is also an antiprotozoal agent.
  • the chemical name of this compound is (llbri)-2-[[(lf?)-6,7-Dimethoxy-l,2,3,4-tetrahydroisoquinolin-l-yl]methyl]-3-ethyl-9,10- dimethoxy-4,6,7, 1 1 b-tetrahydro- 1 //-pyrido[2, 1 -ajisoqui noline, and compound has the following structure:
  • dehydroemetine may be accomplished via methods known in the art.
  • compositions that comprise compounds as described herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients.
  • Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g ., Remington’s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modem Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
  • the pharmaceutical compositions may be administered in either single or multiple doses.
  • the pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal, and transdermal routes.
  • the pharmaceutical composition may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
  • Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions that include at least one compound described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer- coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345.
  • Another formulation for use in the methods disclosed herein employ transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts.
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g ., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein.
  • a pharmaceutical excipient When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt of each thereof.
  • kits for preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt of each thereof, and wherein the subject is a high-risk, symptomatic adult patient with confirmed COVID-19 infection not requiring hospitalization.
  • kits for preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and wherein the subject is a high-risk, symptomatic adult patient with confirmed COVID-19 infection not requiring hospitalization.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt of each thereof.
  • kits for preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt of each thereof.
  • methods of preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof.
  • administration occurs prior to viral infection of the subject.
  • methods of preventing a viral infection caused by SARS-CoV-2 or preventing COVID-19 comprise administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, or cephaeline, or a pharmaceutically acceptable salt thereof, or dehydroemetine, or a pharmaceutically acceptable salt thereof, as a single dose.
  • methods of preventing a viral infection caused by SARS-CoV-2 or preventing COVID-19 comprise administering a booster of a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, or cephaeline, or a pharmaceutically acceptable salt thereof, or dehydroemetine, or a pharmaceutically acceptable salt thereof.
  • the booster may be administered concurrently or separately and may or may not be equivalent in amount to the first dose.
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by a coronavirus.
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by a coronavirus.
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by a coronavirus.
  • the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof.
  • methods of treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, wherein: the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2); the subject does not require hospitalization; and the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 3 mg to about 65 mg per day.
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • the subject does not require hospitalization
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 3 mg to about 65 mg per day.
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • the subject does not require hospitalization
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 3 mg to about 65 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 1 mg/kg of the subject’s body weight to about 1000 mg/kg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg/kg of the subject’s body weight to about 500 mg/kg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg/kg of the subject’s body weight to about 250 mg/kg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg/kg of the subject’s body weight to about 100 mg/kg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 1 mg/kg of the subject’s body weight to about 50 mg/kg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg/kg of the subject’s body weight to about 10 mg/kg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.1 mg/kg of the subject’s body weight to about 1 mg/kg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 1 mg/kg of the subject’s body weight to about 10 mg/kg per day and administered for 10 days. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg/kg of the subject’s body weight per day and administered for 10 days.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 0.1 mg/kg of the subject’s body weight per day and administered for more than 1 day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.1 mg/kg of the subject’s body weight per day and is administered after the subject is administered an initial dose of more than 0.1 mg/kg of the subject’s body weight. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.01 mg/kg of the subject’s body weight to about 0.1 mg/kg of the subject’s body weight per day. [0073] Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof. day.
  • emetine, or a pharmaceutically acceptable salt thereof is administered by a subcutaneous injection. In some embodiments, emetine, or a pharmaceutically acceptable salt thereof, is administered as a sterile subcutaneous injection. In some embodiments, emetine, or a pharmaceutically acceptable salt thereof, is administered orally. In some embodiments, emetine, or a pharmaceutically acceptable salt thereof, is administered by or intramuscular injection.
  • emetine is administered as ipecac syrup.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 1 mg to about 1000 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 1 mg to about 500 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 1 mg to about 50 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 120 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 100 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is 50 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 30 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 1 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 70 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 3 mg to about 65 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 5 mg to about 15 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 5 mg to about 10 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 0.01 mg to about 5 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.05 mg to about 10 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.05 mg to about 5 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 5 mg to about 7 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 6 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 10 mg. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 50 mg. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 100 mg. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 150 mg. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 10 mg to about 175 mg.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 65 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 60 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is 60 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 30 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 10 mg per day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 5 mg per day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 10 mg per day for 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 0.01 mg to about 5 mg per day in 3, 4, 5, 6, or 7 doses. In some embodiments, the doses may be given on every other day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 0.5 mg to about 5 mg per day in 3, 4, 5, 6, or 7 doses. In some embodiments, the doses may be given on every other day. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 5 mg per day in 3, 4, 5, 6, or 7 doses. In some embodiments, the doses may be given on every other day.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 120 mg per day and is administered in one or two doses. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 120 mg per day and is administered subcutaneously in one or two doses.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 60 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days. In some embodiments, about 60 mg per day of emetine, or a pharmaceutically acceptable salt thereof, is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 0.5 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 1 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 5 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days.
  • the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof is about 10 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 20 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days. In some embodiments, the therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, is about 30 mg per day and is administered to the subject in need thereof for at least 1 day and up to 10 days.
  • about 0.5 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • 1 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 5 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 10 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days. In some embodiments, about 20 mg per day of emetine, or a pharmaceutically acceptable salt thereof, is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days. In some embodiments, about 30 mg per day of emetine, or a pharmaceutically acceptable salt thereof, is administered to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 0.5 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 1 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 5 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 10 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days. In some embodiments, about 20 mg per day of emetine, or a pharmaceutically acceptable salt thereof, is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days. In some embodiments, about 30 mg per day of emetine, or a pharmaceutically acceptable salt thereof, is administered subcutaneously to the subject in need thereof for less than 7 days, less than 6 days, or less than 5 days.
  • about 10 mg per day of emetine, or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof for 1 day, followed by about 5 mg per day of emetine, or a pharmaceutically acceptable salt thereof, for up to 13 days, up to 10 days, up to 9 days, or up to 8 days.
  • Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering a therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof.
  • the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof is about 1 mg to about 1000 mg per day. In some embodiments, the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, is 1 mg to about 500 mg per day. In some embodiments, the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, is 1 mg to about 50 mg per day. In some embodiments, the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, is 100 mg per day. In some embodiments, the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, is 50 mg per day. In some embodiments, the therapeutically effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, is 1 mg per day.
  • kits for treating COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof.
  • the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof is about 1 mg to about 1000 mg per day. In some embodiments, the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, is 1 mg to about 500 mg per day. In some embodiments, the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, is 1 mg to about 50 mg per day. In some embodiments, the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, is 100 mg per day. In some embodiments, the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, is 50 mg per day. In some embodiments, the therapeutically effective amount of dehydroemetine, or a pharmaceutically acceptable salt thereof, is 1 mg per day.
  • the subject is a human. In some embodiments, the subject is a human of at least 18 years of age. In some embodiments, the subject is a human less than 18 years of age. [0093] In some embodiments, the subject does not require hospitalization. In some embodiments, the subject does not require admission to a hospital. In some embodiments, the subject has a length of stay in a hospital of less than 1 day. In some embodiments, the subject does not require intensive care unit (ICU) admission. In some embodiments, the subject does not require mechanical ventilation. In some embodiments, the subject does not require supplemental oxygen. In some embodiments, the subject exhibits an oxygen saturation level of between about 90% to about 100%.
  • ICU intensive care unit
  • the subject exhibits oxygen saturation levels of between about 95% to about 100%. In some embodiments, the subject exhibits oxygen saturation levels below about 95% but does not exhibit difficulty breathing. In some embodiments, the subject exhibits mild to moderate symptoms. Such symptoms include but are not limited to fever, cough, shortness of breath or difficulty breathing, tiredness, aches, runny nose, sore throat, and/or loss of smell or taste. In some embodiments, the subject is a high-risk, symptomatic adult patient with confirmed COVID-19 infection not requiring hospitalization. In some embodiments, a high-risk patient is over 60 years old and/or has hypertension, has diabetes, has a pulmonary dysfunction, has an immune system disorder, or a combination thereof.
  • SARS-CoV-2 enters cells through angiotensin-converting enzyme 2 (ACE2).
  • ACE2 angiotensin-converting enzyme 2
  • Lung tissue consequently has become the main invasion target of the SARS- CoV-2 virus as the lung expresses high levels of ACE2.
  • tissue- associated macrophages After the virus enters the lungs, tissue- associated macrophages initially respond to the virus via a class of receptors known as pattern- recognition receptors. Once macrophages are activated, a variety of cytokines are released, resulting in the infiltration and activation of multiple other immune cells. These immune cells attack the lung tissue indiscriminately, leading to respiratory distress.
  • Cytokine release syndrome is a form of systemic inflammatory response syndrome that occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate even more white blood cells. Severe cases have been called cytokine storms. CRS occurs when large numbers of white blood cells, including B cells, T cells, natural killer cells, macrophages, dendritic cells, and monocytes are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. This can occur when the immune system is fighting pathogens, as cytokines signal immune cells such as T-cells and macrophages to travel to the site of infection. In addition, cytokines activate those cells, stimulating them to produce more cytokines.
  • CRS chronic myelolism
  • Symptoms of CRS include fever, fatigue, loss of appetite, muscle and joint pain, nausea, vomiting, diarrhea, rashes, fast breathing, rapid heartbeat, low blood pressure, seizures, headache, confusion, delirium, hallucinations, tremor, and loss of coordination. Cytokine storm may be the probable reason for many deaths during the 2019-2020 COVID-19 pandemic.
  • the subject has been exposed to SARS-CoV-2 but does not exhibit symptoms of CRS.
  • the subject is infected with SARS-CoV-2 but does not exhibit symptoms of CRS.
  • the subject does not exhibit severe symptoms of CRS (cytokine storm).
  • the subject requires hospitalization. In some embodiments, the subject requires admission to a hospital. In some embodiments, the subject has a length of stay in a hospital of greater than 1 day. In some embodiments, the subject requires intensive care unit (ICU) admission. In some embodiments, the subject requires mechanical ventilation. In some embodiments, the subject requires supplemental oxygen. In some embodiments, the subject exhibits an oxygen saturation level of less than about 90%. In some embodiments, the subject exhibits an oxygen saturation level of between about 50% to about 95%. In some embodiments, the subject exhibits severe symptoms. Such symptoms include but are not limited to trouble breathing, chest pain or pressure, confusion or inability to arouse, and/or blue lips or face. In some embodiments, the subject exhibits severe symptoms of CRS (cytokine storm).
  • CRS cytokine storm
  • methods provided herein further comprise administering an additional therapeutic agent.
  • the additional therapeutic agent is administered simultaneously, prior, or after administration of emetine, cephaeline, dehydroemetine, or a pharmaceutically acceptable salt of each thereof.
  • the additional therapeutic agent is an antiparasitic agent.
  • the antiparasitic agent is chloroquine, hydroxycloroquine sulfate, mefloquine, or amodiaquine. In some embodiments, the antiparasitic agent is chloroquine or hydroxychloroquine. In some embodiments, the antiparasitic agent is chloroquine. In some embodiments, the antiparasitic agent is hydroxychloroquine.
  • the additional therapeutic agent is an antibiotic. Non-limiting examples of an antibiotic include monesin sodium, oligomycin, and dihydrocelastryl diacetate. In some embodiments, the antibiotic is azithromycin.
  • the additional therapeutic agent is a corticosteroid.
  • corticosteroids include prednisone, bethamethasone, hydrocortisone, dexamethasone, fludrocortisone, and the like.
  • the additional therapeutic agent is dexamethasone.
  • the additional therapeutic agent is a niclosamide, an emricasan compound, a cyclin-dependent kinase (CDK) inhibitor (including but not limited to palbociclib, ribociclib, and abemaciclib), or a proteasome inhibitor (including but not limited to bortzomib, carfilzomib, and ixazomib).
  • CDK cyclin-dependent kinase
  • the additional therapeutic agent is teriflunomide, hydroxocobalamin, ensulizole, tenonitrozole, isoliquiritigenin, nitazoxanide, febuxostat, leflunomide, vidofludimus, SB-366791, emodin, diphenyl isophthalate, benzoylpas, fenobam, indobufen, 2-(2H-Benzotriazol-2-yl)-4-methylphenol, tiaprofenic acid, flufenamic acid, vitamin B12, cinanserin, 5-Nitro-2-(3-phenylpropylamino)benzoic acid, veliflapon, thiabendazole, SIB 1893, anethole trithione, naringenin, phenazopyridine, fanetizole, terazosin, diacerein, CAY10505, hesperetin,
  • the antiviral agent is amantadine, ampligen, umifenovir, baloxavir marboxil, ganciclovir, letermovir, moroxydine, nitazoxanide, oseltamavir, peramivir, pleconaril, rimantadine, or zanamivir.
  • the antiviral agent is interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudin, cidofovir, fomivirsen, foscamet, ganciclovir, penciclovir, amantadine, rimantadine, lopinavir, ritonavir, zanamivir, or a combination thereof.
  • the antiviral agent is remdesivir or a pharmaceutically acceptable salt thereof. In some embodiments, the antiviral agent is remdesivir. In some embodiments, the antiviral agent is favipiravir or a pharmaceutically acceptable salt thereof. In some embodiments, the antiviral agent is favipiravir.
  • the antiviral agent is a broad-spectrum inhibitor of a coronavirus.
  • a broad-spectrum inhibitor of a coronavirus are lycorine, mycophenolate mofetil, phenazopyridine, mycophenolic acid, pyrvinium pamoate, monensin sodium, cycloheximide, cetylpyridinium chloride, oligomycin, promazine, diperodon, dihydrocelastryl diacetate, tetrandrine, pristimerin, and chloroquine.
  • the additional therapeutic agent is an agent that can inhibit an inflammatory response.
  • such an agent may be useful for controlling a cytokine storm.
  • agents include sphingosine 1 -phosphate receptor 1 modulators (i.e. ozanimod, fmgolimod, etc.), COX inhibitors (i.e., mesalamine, celecoxib, etc.), CCR2 inhibitor (PF-041789-3), anti-TNF agents, statins (i.e. simvastatin), OX40-Ig fusion proteins, and PPARa./PPARy agonists i.e.
  • the agent useful for controlling a cytokine storm is ozanimod or fmgolimod.
  • the additional therapeutic agent is an anti-IL-6 therapeutic agent.
  • an anti-IL-6 therapeutic agent include tocilizumab, sarilumab, siltuximab, and other agents that target the IL-6 receptor.
  • the additional therapeutic agent is bamlanivimab (LY-CoV555).
  • the additional therpeutic agent is baricitinib or a combination of baricitinib and remdesivir.
  • the additional therapeutic agent is bamlanivimab and etesevimab. In some embodiments, the additional therapeutic agent is etesevimab (LY-C0VOI6, JS016).
  • the additional therapeutic agent is regdanvimab.
  • the additional therapeutic agent is casirivimab, imdevimab, or a combination thereof (formerly REGN-COV2).
  • the additional therapeutic agent is MP0420 (ensovibep), CPI-006, artesunate/pyronaridine (pyramax), Mitigare/Colcrys (Colchicine), GSK4182136/GSK4182137 (VIR-7831/VIR-7832), carrageenan nasal spray (carragelose), regdanvimab/CT-P59 (Regkirona), CD24Fc/SACCOVID (MK-7110), niclosamide(Niclocide), UNI91103, camostat mesilate (Foipan/Foistar), SNG001, aviptadil/RLF-100 (Zyesami), APN01, PMX-30063 (Brilacidin), STI- 2020 (COVI-AMG/COVI-DROPS), abivertinib (STI-5656), or lanadelumab (Takhzyro).
  • MP0420 ensovibep
  • the additional therapeutic agent is casirivimab, imdevimab, a combination of casirivimab and imdevimab, baricitinib, remdesivir, PTC299, PRO 140 (leronlimab), LY-CoV555 (bamlanivimab), lenzilumab, ivermectin, aviptadil (RLF-100), metformin, AT-527, tocilizumab, niclosamide, famotidine, lopinavir-ritonavir (kaletra), infliximab, AZD7442, abivertinib CT-P59, heparin, GSK4182136, JS016, sarilumab, CD24Fc, adalimumab, STI-1499, dexamethasone, PB1046, galidesivir, bucillamine, PF-07304814 (PF-00835321
  • methods provided herein further comprise administering to the subject convalescent plasma.
  • the additional therapeutic agent is an anticoagulation drug.
  • the anti coagulation drug is enoxaparin.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • compositions comprising a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of remdesivir, or a pharmaceutically acceptable salt thereof.
  • kits for treating a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an agent useful for controlling a cytokine storm, or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • compositions comprising a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an agent useful for controlling a cytokine storm, or a pharmaceutically acceptable salt thereof.
  • methods of treating COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an agent for controlling a cytokine storm, or a pharmaceutically acceptable salt thereof.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of remdesivir, or a pharmaceutically acceptable salt thereof.
  • kits for preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of remdesivir, or a pharmaceutically acceptable salt thereof.
  • kits for preventing a viral infection caused by SARS-CoV-2 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of remdesivir, or a pharmaceutically acceptable salt thereof, wherein the subject is a high-risk, symptomatic adult patient with confirmed COVID-19 infection not requiring hospitalization.
  • kits for preventing COVID-19 in a subject in need thereof comprising administering a therapeutically effective amount of emetine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of remdesivir, or a pharmaceutically acceptable salt thereof, wherein the subject is a high-risk, symptomatic adult patient with confirmed COVID-19 infection not requiring hospitalization.
  • Patients are administered 1 mg per day of emetine (or a pharmaceutically acceptable salt thereof), via subcutaneous injection, for 10 days.
  • Primary Endpoints are as follows: virological clearance at day 6 post-inclusion or time to clinical improvement (defined as the time from randomization to an improvement of two points (from status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first).
  • Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through 60 days after the last dose.
  • Males must use a condom and spermicide from screening through 60 days after the last dose of study drug if the female partner(s) is of childbearing potential and must not donate sperm from screening through 60 days after the last dose of study drug. This criterion also applies to males who are surgically sterile.
  • DMC independent, external, and multidisciplinary data monitoring committee
  • Inclusion/exclusion criteria may be modified after Part A is completed and the PK and safety data are evaluated, based on recommendations from the DMC.
  • Age Participant must be >18 years of age inclusive, at the time of signing the informed consent form (ICF).
  • Type of Participant and Disease Characteristics Participants who are:
  • SARS-CoV-2 infection confirmed by reverse transcription polymerase chain reaction (RT- PCR) or other validated test ⁇ 4 days prior to randomization
  • Age >60 or Age >18 with at least one of the following risk factors for severe SARS-CoV-2 infection Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, emphysema Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment Hypertension, requiring at least 1 oral medication for treatment History of organ or stem cell transplant Human immunodeficiency virus (HIV) infection with undetectable HIV RNA level Obesity (BMI > 30)
  • HIV Human immunodeficiency virus
  • Sex Male and/or non-pregnant female:
  • Male participants Males must use a condom and spermicide from screening through 60 days after the last dose of study drug if the female partner(s) is of childbearing potential and must not donate sperm from screening through 60 days after the last dose of study drug. This criterion also applies to males who surgically sterile.
  • Female participants Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through 60 days after the last dose.
  • the Screening Period will occur from Day -4 to Day 0 after the subject has been documented as SARS-CoV-2 positive using a qualitative RT-PCR or other validated test. During this time, screening tests will be performed and the onset of and a list of specific symptoms related to SARS-CoV-2 will be documented.
  • SQ subcutaneous a standard of care as defined in the NIH guidelines excluding other antiviral agents
  • a blinded interim analysis will be performed after the completion of Part A.
  • the DMC will evaluate the safety, PK, and preliminary viral and clinical endpoints data from Part A and determine if the trial should begin enrollment in Part B using the existing doses or if any modifications should be made to the dose and/or regimen based on PK or safety.
  • Part B Phase 3 (Dose Finding):
  • Part B of the study 105 subjects will be randomized to 1 of 4 treatment arms (2 active and 2 placebo), as described in Table 5. Efficacy results including viral load and clinical endpoints from Part B will be combined with data from Part A to determine the emetine dose and schedule to be used in Part C (Efficacy).
  • SQ subcutaneous a Dosage and schedule may change based on findings in Part A b standard of care as defined in the NIH guidelines excluding other antiviral agents Source: https://www.covidl9treatmentguidelines.nih.gov/
  • Part C Phase 3 (Efficacy):
  • N/A not applicable
  • SQ subcutaneous a Dosage and schedule may change based on findings in Parts A and B b standard of care as defined in the NIH guidelines excluding other antiviral agents
  • Part A 1 day in Treatment Arms 1 and 2; 4 days in Treatment Arms 3 and 4
  • Part B 1 day in Treatment Arms 1 and 2; 4 days in Treatment Arms 3 and 4
  • Part C 1 day in Treatment Arms 1 and 2 OR 4 days in Treatment Arms 1 and 2
  • AE adverse event
  • AUC area under the concentration-time curve
  • Cmax maximum plasma concentration
  • Cmin minimum plasma concentration
  • Ct cycle threshold
  • ECG electrocardiogram
  • ICU intensive care unit
  • IgG immunoglobulin G
  • IgM immunoglobulin M
  • IFNy interferon gamma
  • IL-6 interleukin 6
  • LDH lactate dehydrogenase
  • NEWS-2 National Early Warning Score 2
  • PK pharmacokinetics
  • RT-PCR reverse transcription polymerase chain reaction
  • SAE serious adverse events
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus-2
  • SOC standard of care
  • SpCk oxygen saturation by pulse oximetry
  • SQ subcutaneous
  • Tmax time to maximum plasma concentration
  • TNFa tumor necrosis factor, alpha.
  • AE adverse event
  • AUC area under the concentration-time curve
  • Cmax maximum plasma concentration
  • Cmin minimum plasma concentration
  • Ct cycle threshold
  • ECG electrocardiogram
  • ICU intensive care unit
  • IgG immunoglobulin G
  • IgM immunoglobulin M
  • IFNy interferon gamma
  • IL-6 interleukin 6
  • LDH lactate dehydrogenase
  • NEWS-2 National Early Warning Score 2
  • PK pharmacokinetics
  • RT-PCR reverse transcription polymerase chain reaction
  • SAE serious adverse events
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus-2
  • SOC standard of care
  • SpCk oxygen saturation by pulse oximetry
  • SQ subcutaneous
  • Tmax time to maximum plasma concentration
  • TNFa tumor necrosis factor, alpha.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement d'une infection virale provoquée par un Coronavirus (tel que le SARS-CoV-2) et des maladies de coronavirus, telles que la COVID-19.
PCT/US2021/024399 2020-03-26 2021-03-26 Méthodes de traitement d'infections à coronavirus WO2021195521A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063000425P 2020-03-26 2020-03-26
US63/000,425 2020-03-26
US202063023133P 2020-05-11 2020-05-11
US63/023,133 2020-05-11

Publications (1)

Publication Number Publication Date
WO2021195521A1 true WO2021195521A1 (fr) 2021-09-30

Family

ID=77890620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/024399 WO2021195521A1 (fr) 2020-03-26 2021-03-26 Méthodes de traitement d'infections à coronavirus

Country Status (1)

Country Link
WO (1) WO2021195521A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022120209A1 (fr) * 2020-12-04 2022-06-09 Acer Therapeutics, Inc. Formes solide de l'émétine
CN115957201A (zh) * 2021-10-08 2023-04-14 中国医学科学院药物研究所 异甘草素在制备防治冠状病毒感染药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149545A1 (en) * 2003-05-28 2009-06-11 Tsu-An Hsu Treatment of coronavirus infection
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149545A1 (en) * 2003-05-28 2009-06-11 Tsu-An Hsu Treatment of coronavirus infection
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN BLEASEL, GREGORY PETERSON: "Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses", PHARMACEUTICALS, M D P I AG, CH, vol. 13, no. 3, 1 January 2020 (2020-01-01), CH , pages 51, XP055738734, ISSN: 1424-8247, DOI: 10.3390/ph13030051 *
MEHTA PUJA; MCAULEY DANIEL F; BROWN MICHAEL; SANCHEZ EMILIE; TATTERSALL RACHEL S; MANSON JESSICA J: "COVID-19: consider cytokine storm syndromes and immunosuppression", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 395, no. 10229, 16 March 2020 (2020-03-16), AMSTERDAM, NL , pages 1033 - 1034, XP086105444, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(20)30628-0 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022120209A1 (fr) * 2020-12-04 2022-06-09 Acer Therapeutics, Inc. Formes solide de l'émétine
US11884663B2 (en) 2020-12-04 2024-01-30 Acer Therapeutics, Inc. Solid forms of emetine
CN115957201A (zh) * 2021-10-08 2023-04-14 中国医学科学院药物研究所 异甘草素在制备防治冠状病毒感染药物中的用途

Similar Documents

Publication Publication Date Title
JP6117845B2 (ja) ニタゾキサニドの制御放出医薬配合物
JP5380078B2 (ja) アレナウイルス感染の治療のための抗ウイルス薬剤
JP5393679B2 (ja) アレナウイルス感染症を治療するための抗ウイルス薬
US20220125767A1 (en) Thiazolide compounds for treating viral infections
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
WO2021195521A1 (fr) Méthodes de traitement d'infections à coronavirus
TWI791212B (zh) 維多氟地莫司(Vidofludimus)用於治療或預防病毒性疾病
US20210322390A1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20220193010A1 (en) Methods of using dipivefrin
EA020283B1 (ru) Средство для профилактики и лечения высокопатогенных инфекционных заболеваний
EP4146202A1 (fr) Procédé de traitement d'un patient infecté par un coronavirus avec du nézulcitinib
JP2023520323A (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
TW202200139A (zh) 用於治療冠狀病毒感染之tlr7/8拮抗劑
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
KR20220150348A (ko) 코로나바이러스의 치료에 조합하여 사용하기 위한 pld
Harfouch et al. Therapeutic approaches for COVID 19: Challenges and successes
JP2023531872A (ja) 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法
JP2023519277A (ja) 伝染性ｒｎａウイルス感染症の予防又は治療するための医薬組成物
CN114786659A (zh) 用于治疗汉坦病毒感染的mek抑制剂
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
WO2021242751A1 (fr) Compositions et procédés de traitement de sars-cov-2
US20240358659A1 (en) Uses of Propranolol for Managing Viral Infections
US20240216365A1 (en) Methods and uses of protein disulfide isomerase inhibitory compounds
Islam et al. A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2
WO2021233956A1 (fr) Ézétimibe pour le traitement d'infections par virus à enveloppe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21775537

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21775537

Country of ref document: EP

Kind code of ref document: A1